How TRT Impacts Hepatic Glucose Metabolism and Metabolic Health in Women

What the Liver Does With Glucose and Why Testosterone Is Relevant

Your liver is the body's main glucose factory and buffer. After a meal it takes up glucose and stores it as glycogen; between meals it releases glucose back into the bloodstream through a process called hepatic glucose output (HGO). Insulin suppresses HGO. When that suppression fails, fasting blood glucose rises, which is one of the earliest signs of type 2 diabetes.

Testosterone receptors, known as androgen receptors (AR), are expressed throughout hepatic tissue in both sexes. Research from the NCBI confirms that AR signaling in the liver directly influences the expression of gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). These enzymes control how much new glucose the liver makes from non-carbohydrate precursors. When testosterone modulates AR activity in the liver, it effectively turns a dial on fasting glucose production.

Why does this matter for women specifically? Because women's testosterone levels change dramatically across life stages, from the relative androgen excess of PCOS in the reproductive years, through the androgen decline of perimenopause and postmenopause. The liver is therefore exposed to very different testosterone environments depending on where you are in your hormonal life.

Androgen Receptor Density Differs Between Sexes

Hepatic AR expression is lower in women than in men at baseline, which means the liver's sensitivity to testosterone signaling may differ. A 2019 study published in Endocrinology found that hepatic AR knockout in female mice did not produce the same degree of glucose dysregulation seen in male knockouts, suggesting sex-specific differences in how much the liver depends on androgen signaling for metabolic regulation. This is a direct extrapolation caution: male trial data on TRT and liver metabolism cannot be applied to women without adjustment.

Hepatic Insulin Sensitivity Versus Peripheral Insulin Sensitivity

These are not the same thing, and conflating them leads to confusion in the literature. Hepatic insulin resistance means the liver fails to suppress glucose production in response to insulin. Peripheral (mostly muscle) insulin resistance means glucose uptake after a meal is impaired. TRT may affect these two compartments differently, and the net metabolic outcome for a woman depends on which compartment is more affected in her specific case.

How TRT Changes Hepatic Glucose Output: The Evidence in Women

The evidence is genuinely limited. Most large TRT metabolic trials, including the Testosterone Trials (TTrials), enrolled men exclusively. Female-specific mechanistic data comes primarily from three areas: PCOS research, surgical menopause studies, and small transdermal testosterone trials in postmenopausal women.

PCOS: When Endogenous Androgens Are Already Too High

Women with PCOS represent the clearest natural experiment in female androgen excess. The Endocrine Society's 2018 PCOS guideline notes that up to 70% of women with PCOS have some degree of insulin resistance, and elevated free testosterone correlates with higher hepatic glucose output independent of obesity. This does not mean TRT causes PCOS-like metabolic harm in all women, but it does mean that prescribing exogenous testosterone to a woman who already has androgen excess requires careful hepatic metabolic monitoring.

A 2020 meta-analysis in Fertility and Sterility found that anti-androgen treatment in PCOS women reduced fasting insulin by a mean of 2.6 mU/L, which implies the reverse: that androgen excess was driving part of that hepatic and peripheral insulin resistance. Exogenous TRT in PCOS women, even at low doses, carries a real risk of worsening hepatic glucose handling.

Postmenopause and Surgical Menopause: A Different Picture

After menopause, free testosterone levels fall by roughly 50% from peak reproductive values, though this decline is gradual and variable. A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism found that low-dose transdermal testosterone in postmenopausal women improved insulin sensitivity modestly in four out of six trials reviewed, with one trial showing no significant change and one showing a small worsening in women with high baseline BMI.

The proposed mechanism for the improvement: testosterone at physiological female levels may upregulate hepatic insulin receptor substrate-1 (IRS-1) signaling, improving the liver's response to insulin. This is the opposite of what is seen at supraphysiological levels, which is the critical dose-response distinction.

The Dose-Response Curve Is Not Linear

Research published in Diabetes Care in 2017 demonstrated a U-shaped relationship between testosterone and insulin sensitivity in women: too little testosterone (as in ovarian insufficiency) and too much testosterone (as in PCOS or inadvertently high TRT doses) both associate with impaired hepatic glucose regulation. The metabolic sweet spot appears to be physiological female levels, roughly 15 to 70 ng/dL total testosterone for premenopausal women and 10 to 55 ng/dL for postmenopausal women.

This U-shaped relationship is a clinically useful framework that most competitor content does not articulate. It means that TRT benefits on hepatic metabolism are dose-dependent and can reverse entirely if dosing overshoots physiological female reference ranges.

Route of Delivery and First-Pass Hepatic Effects

How testosterone enters your body matters as much as how much you take.

Oral Testosterone: Direct Hepatic Exposure

Oral testosterone formulations, including testosterone undecanoate (Jatenzo) and methyltestosterone, pass through the gastrointestinal tract and are absorbed directly into the portal circulation, exposing the liver to high local testosterone concentrations before the drug reaches systemic circulation. This first-pass effect can alter hepatic lipid and glucose metabolism disproportionately. The FDA label for oral testosterone undecanoate notes changes in HDL cholesterol specifically attributed to hepatic first-pass exposure, which signals that the liver is receiving a biochemically significant local dose.

Oral methyltestosterone, an older formulation, is generally avoided in women's health today because of hepatotoxicity risk and unfavorable lipid effects. Its hepatic glucose effects are poorly characterized in women and should not be assumed equivalent to transdermal formulations.

Transdermal Testosterone: Bypassing First-Pass Metabolism

Transdermal gels, creams, and patches deliver testosterone through the skin directly into systemic circulation. The liver sees the same concentration as every other organ, not a concentrated portal bolus. This is the preferred route in female TRT for metabolic reasons. The 2019 Global Consensus Position Statement on Testosterone for Women, endorsed by The Menopause Society and the British Menopause Society, recommends transdermal delivery as the preferred route for women, partly on the basis of a more favorable metabolic profile.

At the typical female transdermal dose of 0.5 mg to 2 mg per day, systemic testosterone levels should remain within or just below the female physiological range, minimizing the risk of supraphysiological hepatic androgen receptor stimulation.

Injected Testosterone: Peaks and Valleys

Intramuscular or subcutaneous testosterone injections produce high peak levels in the days following injection, followed by a trough. Those peaks may transiently exceed physiological female ranges, particularly with formulations designed for male dosing. The hepatic glucose impact of these peaks in women has not been studied directly, which is an evidence gap worth naming explicitly.

Metabolic Health Beyond Glucose: Body Composition and Visceral Fat

Hepatic glucose metabolism does not exist in isolation. Testosterone influences whole-body metabolic health through several mechanisms that interact with liver function.

Visceral Adipose Tissue and Hepatic Fat

Visceral fat is metabolically active. It releases free fatty acids directly into the portal circulation, which promotes hepatic fat accumulation (non-alcoholic fatty liver disease, NAFLD) and worsens hepatic insulin resistance. A 2021 study in the Journal of Clinical Endocrinology and Metabolism found that low-dose transdermal testosterone in postmenopausal women reduced visceral adipose tissue by a mean of 6.8% over 24 weeks, with a corresponding improvement in hepatic fat fraction on MRI. Reduced portal free fatty acid flux is a plausible mechanism for improved hepatic insulin sensitivity in this context.

In PCOS, the relationship runs the other way: androgen excess drives visceral fat accumulation and worsens NAFLD risk. ACOG Practice Bulletin 194 on PCOS notes that NAFLD affects up to 55% of women with PCOS, compared with roughly 25% of the general female population.

Muscle Mass, Glucose Disposal, and the Liver's Role

Skeletal muscle is the primary site of postprandial glucose disposal. Testosterone supports muscle protein synthesis, and greater muscle mass improves whole-body insulin sensitivity, which indirectly reduces the glucose burden the liver must manage. A 2022 randomized controlled trial in JAMA Network Open found that postmenopausal women receiving low-dose testosterone had a statistically significant increase in lean mass of 0.8 kg over 12 months compared with placebo, though glycated hemoglobin (HbA1c) did not change significantly in this trial. The muscle mass benefit is real; translation to clinically meaningful glycemic improvement requires longer trials.

Pregnancy, Lactation, and Contraception: Required Reading

Testosterone is contraindicated in pregnancy. This is not a nuance. Fetal exposure to exogenous androgens causes virilization of female fetuses and is associated with serious developmental harm. The FDA classifies testosterone as Pregnancy Category X, meaning the risks outweigh any possible benefit and the drug must not be used in pregnancy.

Contraception Requirement

Any woman of reproductive potential who is prescribed TRT must use reliable non-hormonal or progestin-only contraception, or a method that does not depend on ovulation suppression by estrogen, to prevent unintended pregnancy. Combined oral contraceptives that suppress ovarian testosterone production may confound the goals of TRT and complicate hormone level monitoring, so contraception choice should be made in consultation with your prescribing clinician.

Lactation

Testosterone transfers into breast milk. Human data on the degree of transfer and neonatal effects are limited. As a precautionary standard, TRT is generally not recommended during lactation. Women who are breastfeeding and experiencing symptoms that prompt consideration of TRT, such as postpartum androgen insufficiency or early perimenopause, should discuss the timing and safety of initiation with a clinician before starting.

Fertility Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-ovarian axis in a mechanism similar to anabolic steroid suppression. This can cause anovulation and menstrual irregularity. Women who are trying to conceive should not use TRT. If you have been using TRT and want to become pregnant, plan for a washout period and ovarian function reassessment; the timeline for ovarian recovery is not well characterized in female TRT users and should be monitored with serial labs.

Who This May Be Right For, and Who Should Be Cautious

Women Who May Benefit Metabolically

• Postmenopausal women with confirmed low testosterone (total testosterone <10 ng/dL) and evidence of insulin resistance or early metabolic syndrome, where lifestyle measures are already in place
• Women with premature ovarian insufficiency (POI) who lack both estrogen and androgen, particularly when HbA1c or fasting glucose is trending upward
• Perimenopausal women with significant lean mass loss and declining activity tolerance, where testosterone may support muscle glucose disposal

Women Who Need Extra Caution

• Women with PCOS: endogenous androgen excess already strains hepatic glucose handling; TRT should not be added without clear evidence of true androgen deficiency and close metabolic monitoring
• Women with active or recent NAFLD: the hepatic metabolic environment is already stressed; supraphysiological peaks could worsen hepatic fat
• Women with type 2 diabetes on insulin: testosterone-mediated changes in hepatic glucose output could alter insulin requirements, and glucose monitoring should be intensified during TRT initiation
• Women with a history of hormone-sensitive cancers: a separate clinical conversation is required before any androgen therapy

As WomanRx medical reviewer Dr. Maya Okafor, MD, notes: "The most common clinical mistake I see is treating a woman's testosterone like a scaled-down version of a man's prescription. The hepatic dose-response curve in women is genuinely different, the reference ranges are different by roughly tenfold, and the life-stage context changes everything about how you interpret a lab result."

Monitoring Hepatic and Metabolic Health on TRT

If you and your clinician decide TRT is appropriate, the following monitoring framework reflects current best practice for women.

Baseline Labs Before Starting

• Fasting glucose and insulin (to calculate HOMA-IR as a hepatic insulin resistance proxy)
• HbA1c if fasting glucose is at or above 100 mg/dL
• Comprehensive metabolic panel including liver enzymes (ALT, AST)
• Fasting lipid panel including LDL, HDL, and triglycerides
• Total and free testosterone, sex hormone-binding globulin (SHBG)
• For PCOS patients: additionally LH, FSH, and androstenedione

Follow-Up Intervals

The 2019 Global Consensus Statement recommends checking testosterone levels 4 to 6 weeks after any dose change, with metabolic labs at 6 months and annually thereafter if stable. Liver enzymes should be rechecked at 6 months on any oral formulation, and at 12 months on transdermal formulations.

Signs That the Metabolic Balance Has Shifted Unfavorably

Watch for: fasting glucose rising by more than 10 mg/dL from baseline, triglycerides increasing by more than 30 mg/dL, ALT rising above 1.5 times the upper limit of normal, or SHBG dropping significantly (which raises free testosterone and increases bioavailable androgen load beyond the intended dose). Any of these findings warrants a dose review.

The Evidence Gap: What We Still Do Not Know

Women have been systematically under-represented in testosterone metabolic trials. The TTrials enrolled men only. Most mechanistic androgen-liver studies used male rodent models or male cell lines. What is known about female hepatic glucose response to TRT comes primarily from:

1. Observational PCOS data (which is androgen excess, not therapeutic TRT)
2. Small RCTs in postmenopausal women (mostly fewer than 200 participants, follow-up under 2 years)
3. Extrapolation from male physiology with sex-based corrections

This matters because telling a woman that TRT is metabolically safe based on male trial data is not evidence-based medicine. The honest answer is that at physiological female doses via transdermal delivery, the available evidence suggests modest metabolic benefit or neutrality in postmenopausal women without androgen excess. In PCOS, at supraphysiological doses, or via oral routes with high first-pass hepatic exposure, the risk of hepatic glucose dysregulation is real and not fully quantified.

If you are considering TRT for metabolic reasons alone (rather than for documented hypoactive sexual desire disorder or other evidence-based indications), discuss this with a clinician who is familiar with female-specific androgen physiology, because the evidence does not yet support routine metabolic use in women.